Effects of Phenothiazines on Aldehyde Oxidase Activity Towards Aldehydes and N-Heterocycles: an In Vitro and In Silico Study
- 49 Downloads
Aldehyde oxidase (AOX) is an important molybdenum-containing enzyme with high similarity with xanthine oxidase (XO). AOX involved in the metabolism of a large array of aldehydes and N-heterocyclic compounds and its activity is highly substrate-dependent.
The aim of this work was to study the effect of five important phenothiazine drugs on AOX activity using benzaldehyde and phenanthridine as aldehyde and N-heterocyclic substrates, respectively.
The effect of trifluperazine, chlorpromazine, perphenazine, thioridazine and promethazine on rat liver AOX was measured spectrophotometrically. To predict the mode of interactions between the studied compounds and AOX, a combination of homology modeling and a molecular docking study was performed.
All phenothiazines could inhibit AOX activity measured either by phenanthridine or benzaldehyde with almost no effect on XO activity. In the case of benzaldehyde oxidation, the lowest and highest half-maximal inhibitory concentration (IC50) values were obtained for promethazine (IC50 = 0.9 µM), and trifluoperazine (IC50 = 3.9 µM), respectively; whereas perphenazine (IC50 = 4.3 µM), and trifluoperazine (IC50 = 49.6 µM) showed the strongest and weakest inhibitory activity against AOX-catalyzed phenanthridine oxidation, respectively. The in silico findings revealed that the binding site of thioridazine is near the dimer interference, and that hydrophobic interactions are of great importance in all the tested phenothiazines.
The five studied phenothiazine drugs showed dual inhibitory effects on AOX activity towards aldehydes and N-heterocycles as two major classes of enzyme substrates. Most of the interactions between the phenothiazine-related drugs and AOX in the binding pocket showed a hydrophobic nature.
The work was a part of a MSc thesis and the authors are grateful to the School of Pharmacy and Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran, for providing the necessary facilities during this work.
Compliance with Ethical Standards
No funding was received for the conduct of this study.
Conflict of Interest
All the authors have no conflict of interest to declare.
The study was approved by the local and national ethics committees.
- 1.Argikar UA, Potter PM, Hutzler JM, Marathe PH. Challenges and opportunities with non-CYP enzymes aldehyde oxidase, carboxylesterase, and udp-glucuronosyltransferase: focus on reaction phenotyping and prediction of human clearance. AAPS J. 2016;18(6):1391–405. https://doi.org/10.1208/s12248-016-9962-6.Google Scholar
- 5.Rashidi MR, Smith JA, Clarke SE, Beedham C. In vitro oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit, and rat liver. Drug Metab Dispos. 1997;25(7):805–13.Google Scholar
- 6.Beedham C, Miceli JJ, Obach RS. Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J Clin Psychopharmacol. 2003;23(3):229–32. https://doi.org/10.1097/01.jcp.0000084028.22282.f2.Google Scholar
- 7.Rashidi MR, Beedham C, Smith JS, Davaran S. In vitro study of 6-mercaptopurine oxidation catalysed by aldehyde oxidase and xanthine oxidase. Drug Metab Pharmacokinet. 2007;22(4):299–306.Google Scholar
- 9.Jordan CG, Rashidi MR, Laljee H, Clarke SE, Brown JE, Beedham C. Aldehyde oxidase-catalysed oxidation of methotrexate in the liver of guinea-pig, rabbit and man. J Pharm Pharmacol. 1999;51(4):411–8.Google Scholar
- 18.Tayama Y, Sugihara K, Sanoh S, Miyake K, Morita S, Kitamura S, et al. Effect of tea beverages on aldehyde oxidase activity. Drug Metab Pharmacokinet. 2011;26(1):94–101.Google Scholar
- 23.Pirouzpanah S, Rashidi MR, Delazar A, Razavieh SV, Hamidi A. Inhibitory effects of Ruta graveolens L. extract on guinea pig liver aldehyde oxidase. Chem Pharm Bull. 2006;54(1):9–13.Google Scholar
- 24.Johnson C, Stubley-Beedham C, Stell JG. Hydralazine: a potent inhibitor of aldehyde oxidase activity in vitro and in vivo. Biochem Pharmacol. 1985;34(24):4251–6.Google Scholar
- 29.Schwede T, Kopp J, Guex N, Peitsch MC. SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res. 2003;31(13):3381–5.Google Scholar
- 31.Melo F, Devos D, Depiereux E, Feytmans E. ANOLEA: a www server to assess protein structures. Proc Int Conf Intell Syst Mol Biol. 1997;5:187–90.Google Scholar
- 32.Froimowitz M. HyperChem: a software package for computational chemistry and molecular modeling. Biotechniques. 1993;14(6):1010–3.Google Scholar
- 36.Grant JA, Gallardo MA, Pickup BT. A fast method of molecular shape comparison: a simple application of a Gaussian description of molecular shape. J Comput Chem. 1996;17(14):1653–66. https://doi.org/10.1002/(sici)1096-987x(19961115)17:14%3c1653:aid-jcc7%3e3.0.co;2-k.Google Scholar
- 37.Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: a program to generate schematic diagrams of protein–ligand interactions. Protein Eng. 1995;8(2):127–34.Google Scholar
- 42.Brunton LL, Gilman A, Goodman LS. Goodman and Gilman’s the pharmacological basis of therapeutics. New York: McGraw-Hill; 2006.Google Scholar
- 43.Eggert Hansen C, Rosted Christensen T, Elley J, Bolvig Hansen L, Kragh-Sorensen P, Larsen NE, et al. Clinical pharmacokinetic studies of perphenazine. Br J Clin Pharmacol. 1976;3(5):915–23.Google Scholar
- 44.Wallace JE, Shimek EL Jr, Harris SC, Stavchansky S. Determination of promethazine in serum by liquid chromatography. Clin Chem. 1981;27(2):253–5.Google Scholar
- 46.Midha KK, Korchinski ED, Verbeeck RK, Roscoe RM, Hawes EM, Cooper JK, et al. Kinetics of oral trifluoperazine disposition in man. Br J Clin Pharmacol. 1983;15(3):380–2.Google Scholar